FDA clears 1st nucleic acid-based test for central nervous system infections for marketing

The FDA has approved marketing for the first “cerebrospinal fluid nucleic acid-based test for simultaneous detection of multiple pathogens that can cause central nervous system infections,” according to HHS.

Advertisement

Called the FilmArray Meningitis/Encephalitis Panel, the fluid is intended to test for 14 bacterial, viral and yeast pathogens with a CSF sample. The test should be able to yield results in an hour.

 

The FDA emphasizes this test is not a replacement for standard CSF bacterial and fungal cultures, but rather an addition.

 

BioFire Diagnostics in Salt Lake City manufactures the FilmArray ME Panel.

 

More articles on spine:
CNS past president Dr. Nathan Selden joins Cerebrotech’s scientific advisory board: 5 key notes
Drs. Joseph Zabramski, William Hunter & more: 12 spine surgeons in the headlines this week
Where non-operative spine specialists fit in the future: What surgeons need to know

Advertisement

Next Up in Spine

Advertisement

Comments are closed.